Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer

NCT01843062 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01843062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01843062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
August 27, 2013
Completion date
March 6, 2019
Enrollment
233 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid cancer